# Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

> **NCT02122822** · PHASE1 · COMPLETED · sponsor: **Cure&Sure Biotech Co., LTD** · enrollment: 20 (actual)

## Conditions studied

- Glioma

## Interventions

- **BIOLOGICAL:** gp96

## Key facts

- **NCT ID:** NCT02122822
- **Lead sponsor:** Cure&Sure Biotech Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2015-07
- **Final completion:** 2017-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02122822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02122822, "Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02122822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*